Category: Uncategorized

DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT) today announced that it will report its financial results for the second fiscal quarter ended September 30, 2026 on Monday, November 9, 2026 before the market opens. Roivant Sciences Ltd. (Nasdaq: ROIV), Immunovant’s majority stockholder, will host a live conference call and webcast at 8:00 a.m. ET that same day, which will include a business update for Immunovant.

To access the Roivant conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant’s website after the conference call.

About Immunovant 

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases and is a majority-owned subsidiary of Roivant. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com. 

Contacts: 

Investors

Keyur Parekh
[email protected]

Media

Stephanie Lee
[email protected]

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) — SueWallSt encourages investors who suffered losses in Ryde Group Ltd (NYSE: RYDE) to contact the firm. Those who purchased RYDE securities between March 6, 2024 and September 11, 2024 may be entitled to recover damages. Find out if you may be eligible to recover losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

RYDE peaked at $22.49 before reportedly faltering to only $5.50 per share on September 11, 2024. The window to apply for lead plaintiff closes on November 9, 2026.

The Named Individual Defendants

Six insiders are identified as individual defendants: Chief Executive Officer Junming Terence Zou, Chief Financial Officer Chen Fei Lang, and directors Ting Yong Tan, Su Nee Joanne Khoo, Venkata Subramanian s/o Sreenivasan, and Wai Hong Poon, who served until August 22, 2024. The February 12, 2024 registration statement was signed by Zou and Lang, and Zou certified the Company’s 2023 annual report on Form 20-F, the securities action alleges.

Sarbanes-Oxley Certification Obligations

Officer certifications under Sarbanes-Oxley Sections 302 and 906 place personal responsibility on the signing executives for the accuracy of what a company tells the market. The action also pleads Section 20(a) of the Exchange Act, which in practical terms means insiders who controlled the Company may be held jointly responsible for its alleged violations.

Alleged Control Person Liability

• Each individual defendant allegedly possessed the power to control the contents of RYDE’s SEC reports, press releases, and presentations to money managers and institutional investors.
• The officers who signed the offering documents allegedly attested to consolidated financial statements presented as conforming to U.S. GAAP, which the action claims they were not.
• The chief executive allegedly certified the 2023 Form 20-F, which repeated the “Super mobility app” business description while omitting the alleged social media promotion campaign surrounding the stock.
• Directors allegedly received copies of the challenged reports and releases before or shortly after issuance and had the opportunity to prevent or correct them.
• No individual defendant issued a cautionary statement as outsized price swings and impersonator-run chat group promotion became publicly observable, as claimed.
• The action further names the Company’s auditor, IPO underwriter, and process agent as gatekeepers who allegedly could have stopped the filings at issue.

“Corporate officers have a duty to ensure their companies’ public statements are accurate and complete. Here, the complaint alleges that the executives who signed and certified RYDE’s filings never told shareholders that the stock’s run from $4.00 to $22.49 bore no relationship to the business they described.” — Joseph E. Levi, Esq.

Submit your information to learn more or call (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the RYDE Lawsuit

Q: Who are the defendants named in the RYDE lawsuit? A: The complaint names Ryde Group Ltd and individual defendants including senior executives who signed SEC filings, made public statements, or certified financial disclosures under Sarbanes-Oxley.

Q: What court was the RYDE class action filed in? A: The case was filed in the United States District Court for the Southern District of New York, governed by the Private Securities Litigation Reform Act of 1995.

Q: What is the RYDE class action lawsuit about? A: A securities class action has been filed against Ryde Group Ltd (NYSE: RYDE) alleging materially false and misleading statements between March 6, 2024 and September 11, 2024. Shares fell 75% from their peak in a single trading session. Investors who purchased shares during the Class Period and suffered losses may be eligible to seek compensation.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What do RYDE investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible as an absent class member.

Q: What if I already sold my RYDE shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in the securities class action, they are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval.

CONTACT:\

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (888) SueWallSt

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) that a securities class action has been filed on behalf of shareholders who purchased securities between December 29, 2025 and June 29, 2026. Submit your information. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

UNCY closed at $7.70 on June 29, 2026. The next morning, shares fell $3.01, or 39.1%, to close at $4.69 on unusually heavy trading volume. Lead plaintiff applications must be submitted by November 2, 2026.

Why the June 30 Announcement Allegedly Mattered to Shareholders

On June 30, 2026, before the market opened, the Company announced that the FDA had issued a Complete Response Letter on the resubmitted OLC New Drug Application based on the “same third-party manufacturing deficiencies that were identified in the previous CRL issued in June 2025.” The same announcement stated that the FDA had not yet conducted its inspection of that vendor during the resubmission review, and that the resubmission had been made based on the Company’s “belief” of continued progress by the vendor. The action alleges that shareholders were never told the Company had not inspected or audited the vendor’s facility for compliance with current good manufacturing practices before resubmitting the application.

Rights Available to UNCY Purchasers

• Eligibility turns on purchase timing. Investors who acquired UNCY securities between December 29, 2025 and June 29, 2026 and suffered losses may be class members.
• Any class member may ask the court for appointment as lead plaintiff, a role courts typically award to the investor with the largest documented loss.
• Investors who have already sold their shares may still be eligible, because eligibility is based on when shares were purchased.
• Class members who take no action before the deadline may still share in any recovery that is ultimately obtained.
• Investors choose their own counsel and may have their brokerage records reviewed at no cost and with no obligation.

No Upfront Cost to Review a Potential Claim

Having a claim evaluated costs nothing. Securities class actions are generally handled on a contingency basis, with any attorneys’ fees and expenses subject to court approval. The overwhelming majority of class members never appear in court or give testimony.

“Shareholders who bought UNCY during the Class Period have rights under the federal securities laws whether or not they still hold the stock,” said Joseph E. Levi, Esq. “Plaintiffs contend that investors were told the OLC resubmission rested on vendor progress that the Company itself had never verified through an inspection. Investors are entitled to have that allegation tested.”

Act now. Click here to learn more or call (212) 363-7500.

ABOUT LEVI & KORSINSKY, LLP — Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report. Investors who suffered losses have until November 2, 2026 to seek appointment as lead plaintiff.

Frequently Asked Questions About the UNCY Lawsuit

Q: Who is eligible to join the UNCY investor lawsuit? A: Investors who purchased UNCY stock or securities between December 29, 2025 and June 29, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.

Q: What is the UNCY lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is November 2, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.

Q: How much did UNCY stock drop? A: Shares fell approximately 39.1%, a decline of $3.01 per share, after the Company disclosed that the FDA had issued a second Complete Response Letter based on the same third-party manufacturing deficiencies identified in the prior CRL. Investors who purchased shares during the Class Period at artificially inflated prices and suffered losses may be eligible to seek compensation.

Q: What do UNCY investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible as an absent class member.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What if I already sold my UNCY shares — can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.

Q: What if I missed the lead plaintiff deadline? A: The deadline applies only to investors seeking lead plaintiff appointment. Class members who miss it may still be able to participate in any potential settlement or recovery.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

NEW YORK, Oct. 05, 2026 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Lincoln Educational Services Corporation (NASDAQ: LINC) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between May 11, 2026 and August 9, 2026. See if you could be eligible to recover. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

LINC closed at a Class Period high of $55.68 on July 7, 2026. On August 10, 2026, the shares fell $10.22, or 24.93%, to close at $30.77 on unusually heavy trading volume. Investors have until November 10, 2026 to seek lead plaintiff status.

May 11, 2026: The Class Period Opens With Raised Guidance

The securities action alleges that on this date the Company reported first quarter results and raised its 2026 outlook, citing 19.5% student start growth. Management described continuing investment in “people and processes” and improving retention. As claimed in the action, the same disclosures omitted that the admissions process was not effectively converting enrolled students into students who actually began attending class.

August 10, 2026: The Conversion Gap Reaches the Market

The Company reported that second quarter student starts rose roughly 1% year over year, stating that “fewer enrolled students than expected attended the first day of class” and that it had “observed changes in the student decision-making process that affected conversion from enrollment to start.” Management also pointed to the resumption of federal student loan repayment in May 2026 and resulting borrower defaults. The lawsuit contends this disclosure corrected prior alleged misstatements, and the shares repriced the same morning.

Timeline of Alleged Disclosure Failures

• May 11, 2026: Class Period begins as 2026 guidance is raised and retention gains are highlighted.
• May 11, 2026: The quarterly report attributes revenue growth to start growth, without disclosing the alleged conversion weakness.
• May 2026: Federal borrowers are required to resume loan repayment, a development management later linked to defaults and softer starts.
• July 7, 2026: LINC closes at its Class Period high of $55.68 per share.
• August 9, 2026: Class Period ends.
• August 10, 2026: Second quarter results disclose approximately 1% start growth and a stated shift in student decision-making.

“Timely disclosure of material developments is fundamental to fair and efficient markets. The sequence here, from raised guidance in May to the August statement that fewer enrolled students than expected attended the first day of class, raises questions the complaint asks the court to examine.” — Joseph E. Levi, Esq.

Calculate your potential recovery
or call (212) 363-7500.

Levi & Korsinsky, LLP — Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

Frequently Asked Questions About the LINC Lawsuit

Q: What specific misstatements does the LINC lawsuit allege? A: The complaint alleges Lincoln Educational Services made materially false or misleading statements regarding the effectiveness of its admissions process and the conversion of enrolled students into actual student starts during the Class Period. When the Company disclosed that second quarter student starts grew only about 1% despite 9% enrollment growth because fewer enrolled students than expected attended the first day of class, the stock price declined sharply.

Q: When did Lincoln Educational Services allegedly mislead investors? A: The Class Period runs from May 11, 2026 to August 9, 2026. The complaint alleges that corrective disclosures revealed information that caused a significant stock decline.

Q: What court was the LINC class action filed in? A: The case was filed in the United States District Court for the District of New Jersey, governed by the Private Securities Litigation Reform Act of 1995.

Q: What do LINC investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible as an absent class member.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What if I already sold my LINC shares, can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.

Q: How long will the lawsuit take to resolve? A: Securities class actions typically take two to four years from initial filing to resolution. Timing depends on the court schedule, case developments, and whether the matter is dismissed, settled, or litigated further.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (212) 363-7500

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

AUSTIN, Texas, Oct. 05, 2026 (GLOBE NEWSWIRE) — FTC Solar, Inc. (Nasdaq: FTCI), a leading provider of solar tracker systems, software, and engineering services, announced today that it has entered into an amended credit agreement with its lenders, relating primarily to the principal prepayment terms and the financial covenants that would have applied during the remainder of 2026.

Key terms of the amendment include the following:

• Deferral of $5 million cash repayment requirement that was otherwise due September, 30, 2026 to March 31, 2027
• No financial covenants apply to the third quarter of 2026 and will not apply to the fourth quarter of 2026
• Future cash balance covenant adjusted to $15 million and will be tested starting January 4, 2027
• Removal of full-year 2026 adjusted EBITDA covenant
• Introduction of first quarter 2027 adjusted EBITDA covenant of $2 million
• Other financial covenants (revenue, direct margin, purchase order amounts) begin to apply at the end of the first quarter of 2027

“We’re pleased to announce this amendment, which reflects the strength of our partnership with our lenders, and the progress we continue to make as a company,” said Anthony Carroll, CEO of FTC Solar. “These adjustments provide us with greater flexibility to execute our business strategy and position the company for sustainable, long-term growth, while allowing that growth to develop organically.”

Additional information related to the amended agreement can be found in the Company’s Current Report on Form 8-K filed today with SEC.

About FTC Solar Inc.

Founded in 2017 by a group of renewable energy industry veterans, FTC Solar is a leading provider of solar tracker systems, technology, software, and engineering services. Solar trackers significantly increase energy production at solar power installations by dynamically optimizing solar panel orientation to the sun. FTC Solar’s innovative tracker designs provide compelling performance and reliability, with an industry-leading installation cost-per-watt advantage.

FTC Solar Investor Contact:

Bill Michalek 
Vice President, Investor Relations 
FTC Solar
T: (737) 241-8618 
E: [email protected]

Forward-Looking Statements 
This press release contains forward looking statements. These statements are not historical facts but rather are based on our current expectations and projections regarding our business, operations and other factors relating thereto. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates” and similar expressions are used to identify these forward-looking statements. Specific forward-looking statements in this press release include, without limitation, our expectation that we will have greater flexibility to execute our business strategy and position the company for sustainable, long-term growth, while allowing that growth to develop organically. These statements are only predictions and as such are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. In addition, this press release contains statements about third parties and their commercial activity. We have not independently verified or confirmed such statements and have instead relied on the veracity of information as provided to us by such third parties related to such statements. You should not rely on our forward-looking statements or statements related to third parties or their commercial activities as predictions of future events, as actual results may differ materially from those in the forward-looking statements or statements related to third parties or their commercial activities because of several factors, including those described in more detail above and in our filings with the U.S. Securities and Exchange Commission, including the section entitled “Risk Factors” contained therein. FTC Solar undertakes no duty or obligation to update any forward-looking statements or statements related to third parties or their commercial activities contained in this release as a result of new information, future events or changes in its expectations, except as required by law.

Rapid oral presentation of additional sub-group analyses from the VIKTORIA-1 PIK3CA mutant-type cohort

Poster presentation of a comparative analysis of data for the gedatolisib triplet from the PIK3CA wild-type cohort of VIKTORIA-1 and other regimens evaluated in patients with HR+/HER2- advanced breast cancer

Poster presentation of sub-group analyses from the Phase 1b trial of gedatolisib plus darolutamide in patients with mCRPC

MINNEAPOLIS, Oct. 05, 2026 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that a late breaking rapid oral presentation and three poster presentations will be featured at the upcoming European Society for Medical Oncology (“ESMO”) Congress 2026 being held October 23-27, 2026, in Madrid, Spain. Data from its clinical trials of gedatolisib in hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”) locally advanced or metastatic breast cancer (“ABC”) and metastatic castration-resistant prostate cancer (“mCRPC”) will be presented.

Late Breaking Rapid Oral Presentation Details:

Title: VIKTORIA-1: Updated results of a randomized, open-label, phase 3 study of gedatolisib (geda) + fulvestrant (fulv) ± palbociclib (palbo) vs standard of care in patients with HR+/HER2- advanced breast cancer (ABC) (Study 2)
Presentation Number: LBA 16
Speaker: Barbara Pistilli, MD
Session Title: Rapid oral 1: Breast cancer, advanced stage
Room: Almeria Auditorium – Hall 9
Date: Saturday, October 24, 2026
Time: 10:15 –11:45 a.m. CEST

Poster Presentation Details:

Title: A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC)
Presentation Number: 2237P
Presenting Author: Adam Sharp, MD, PhD
Session Title: Poster Display session, Metastatic prostate cancer
Date: Friday, October 23, 2026
Time: 3:15 p.m. – 4:00 p.m. CEST

Title: Gedatolisib (Ged) vs Other Regimens Post-CDK4/6i and Endocrine Therapy (ET) in PIK3CA Wild-Type (WT) HR+/ HER2- Advanced Breast Cancer (aBC): A Network Meta-Analysis (NMA)
Presentation Number: 1873P
Presenting Author: Sara Tolaney, MD
Session Title: Poster Display session, HR+ breast cancer
Date: Saturday, October 24, 2026
Time: 12:00 p.m. – 12:45 p.m. CEST

Title: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Gedatolisib with Endocrine Therapy (ET) and Palbociclib vs ET and Ribociclib as First-Line (1L) Treatment in Patients With HR-Positive (HR+) HER2-Negative (HER2-) Advanced Breast Cancer (ABC) (VIKTORIA-2)
Presentation Number: 57TiP
Presenting Author: Giuseppe Curigliano, MD, PhD
Session Title: Poster Display session, Advanced breast cancer, other
Date: Saturday, October 24, 2026
Time: 12:00 p.m. – 12:45 p.m. CEST

Abstracts will be published online via the ESMO website at 12:05 a.m. CEST on October 19, 2026. The posters will be presented in the Poster Area – Hall 5. Electronic versions will also be available on the ESMO 2026 virtual platform.

About Celcuity

Celcuity is a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications. The company’s first FDA-approved product is REVTORPYK™ (gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- ABC, supported FDA approval of REVTORPYK for use in patients without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting. Results for the PIK3CA mutant cohort of VIKTORIA-1 have been released. VIKTORIA-2 is an ongoing Phase 3 clinical trial incorporating two independent studies, Study 1 and Study 2, in two separate cohorts of patients with ABC who are treatment-naive in the advanced setting. Study 1 is evaluating gedatolisib plus palbociclib plus fulvestrant as first-line treatment for patients with endocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib plus palbociclib plus letrozole as first-line treatment for patients with endocrine-sensitive HR+/HER2- ABC. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration-resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov. Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com. Follow us on LinkedIn and X.

Contacts: 

For Investors: 
Brian Sullivan, [email protected]
Vicky Hahne, [email protected]   
(763) 392-0123

For investors and media:
Jodi Sievers, [email protected]
(415) 494-9924